Navigation Links
Cancer risk among nuclear industry workers

A cohort multinational study was done involving 598 068 nuclear industry workers from 15 countries.// The study was done to estimate the risk of cancer after administrating low doses of radiation.

This study is an international collaborative study to estimate the cancer risk among radiation workers in the nuclear industry to find out the risk of cancer occurrence after low dose exposure of radiation.

The study recruits were employed in 154 different facilities, involved in nuclear power production, research, waste management and industries of fuel, isotope and weapon. During the study period, about 24,158 (5.9%) of recruits died, 6519 from cancer other than leukaemia and 196 from leukaemia (excluding lymphocytic leukaemia).

Results from the study show that there is an increased risk of cancer exists in the recruits even at a low dose and a significant increase risk for all cancers (excluding leukaemia). Some factors like smoking and diet in recruits can have an association between radiation dose and risk of cancer. Some earlier studies have found associations between radiation dose and smoking and while others have not. Factors such as smoking can confound the association between radiation doses and risk only if they are related both to risk of cancer and to dose.

Current recommendations form the International Commission on Radiological Protection (ICRP) are to limit occupational doses to 100 Sv (sieverts) over five years (not to exceed 50 Sv in any one year) and doses to the public to 1 Sv per year. This study results show that an exposure of 100 Sv will cause 9.7% mortality from cancer (excluding leukaemia), and a 5.9% increased mortality from cancers excluding leukaemia, lung, and pleura.

Our study is the largest study on nuclear industry workers conducted so far, and provides an estimation of radiation risk. These results suggest that there is an increased risk of cancer occurs even at a lower dose of nucle ar radiation.


'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 2016 , ... The West Virginia Medical Institute (WVMI) announced ... name change aligns the entire company with its existing Quality Insights branded projects ... are very proud of the achievements associated with the West Virginia Medical Institute ...
(Date:12/8/2016)... Pennsylvania (PRWEB) , ... December 08, 2016 , ... ... Duck Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which ... , “This was our first franchise-wide Quack Gives Back initiative, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Research and Markets has announced the addition of the "Global ... ... market to grow at a CAGR of 6.83% during the period ... growth prospects of the global travel vaccines market for 2016-2020. To ... the sales of various vaccines administered to actively immunize meningococcal disease, ...
(Date:12/9/2016)... 2016  Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced a ... 2b trial evaluating treatment with intepirdine (RVT-101), combined ... plus placebo in people with mild-to-moderate Alzheimer,s disease. ... to treatment was associated with reduced progression in ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
Breaking Medicine Technology: